Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease

Journal of Neuroimmune Pharmacology

Volumn 9, Issue 4, 2014, Pages 569-581

  Khasnavis, Saurabh ^a   Pahan, Kalipada ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cinnamon; DJ 1; Dopamine; Dopaminergic neurons; MPTP mouse model; Nitric oxide; Parkin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CINNAMON EXTRACT; DJ 1 PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PARKIN; BENZOIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIAL FIBRILLARY ASTROCYTIC PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NOS2 PROTEIN, MOUSE; ONCOPROTEIN; PARK7 PROTEIN, MOUSE; PEROXIREDOXIN; POWDER; PROTEIN DEGLYCASE DJ-1; TUMOR NECROSIS FACTOR; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL ISOLATION; CINNAMON; CYTOKINE PRODUCTION; DOPAMINERGIC NERVE CELL; MOUSE; MOUSE MODEL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPLETION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BARK; BLOOD; CHEMISTRY; CINNAMOMUM; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; MALE; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; PHYTOTHERAPY; POWDER; PRIMARY CELL CULTURE; SUBSTANTIA NIGRA;

ANIMALS; ASTROCYTES; CINNAMOMUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN-1BETA; MALE; MICE; MOTOR ACTIVITY; MPTP POISONING; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; ONCOGENE PROTEINS; PEROXIREDOXINS; PHYTOTHERAPY; PLANT BARK; POWDERS; PRIMARY CELL CULTURE; PROTEIN DEGLYCASE DJ-1; SODIUM BENZOATE; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 84906337071     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-014-9552-2     Document Type: Article

References (36)

1. Abd El-Mawla AM, Schmidt W, Beerhues L (2001) Cinnamic acid is a precursor of benzoic acids in cell cultures of Hypericum androsaemum L. but not in cell cultures of Centaurium erythraea RAFN. Planta 212:288-293 (Pubitemid 32139886)
2. Akama KT, Albanese C, Pestell RG, Van Eldik LJ (1998) Amyloid betapeptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci U S A 95:5795-5800 (Pubitemid 28224176)
3. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101:9435-9440 (Pubitemid 38812892)
4. Bian M, Liu J, Hong X, YuM, Huang Y, Sheng Z, Fei J, Huang F (2013) Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PLoS ONE 7:e39953
5. Brahmachari S, Pahan K (2007) Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive transfer of experimental allergic encephalomyelitis. J Immunol 179:275-283 (Pubitemid 46986543)
6. Brahmachari S, Fung YK, Pahan K (2006) Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci 26:4930-4939 (Pubitemid 44315335)
7. Brahmachari S, Jana A, Pahan K (2009) Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 183:5917-5927
8. Bridges JW, French MR, Smith RL, Williams RT (1970) The fate of benzoic acid in various species. Biochem J 118:47-51
9. Brosnan CF, Battistini L, Raine CS, Dickson DW, Casadevall A, Lee SC (1994) Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci 16:152-161
10. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909 (Pubitemid 37130207)
11. Drapier JC, Hibbs JB Jr (1988) Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 140:2829-2838
12. Fahn S (2010) Parkinson's disease: 10 years of progress, 1997-2007. Mov Disord 25(Suppl 1):S2-S14
13. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mousemodel of Parkinson's disease. ProcNatl AcadSciUSA104:18754-18759 (Pubitemid 350210769)
14. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 29:13543-13556
15. Jana M, Anderson JA, Saha RN, Liu X, Pahan K (2005) Regulation of inducible nitric oxide synthase in proinflammatory cytokine-stimulated human primary astrocytes. Free Radic Biol Med 38:655-664 (Pubitemid 40416861)
16. Jana M, Jana A, Liu X, Ghosh S, Pahan K (2007) Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J Immunol 179:4142-4152
17. Jana A, Modi KK, Roy A, Anderson JA, van Breemen RB, Pahan K (2013) Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: therapeutic implications for neurodegenerative disorders. J Neuroimmune Pharmacol 8:739-755
18. Khasnavis S, Pahan K (2012) Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons. J Neuroimmune Pharmacol 7:424-435
19. Khasnavis S, Jana A, Roy A, Mazumder M, Bhushan B, Wood T, Ghosh S, Watson R, Pahan K (2012) Suppression of nuclear factor-kappaB activation and inflammation in microglia by physically modified saline. J Biol Chem 287:29529-29542
20. Khasnavis S, Roy A, Ghosh S, Watson R, Pahan K (2014) Protection of dopaminergic neurons in a mouse model of parkinson's disease by a physically-modified saline containing charge-stabilized nanobubbles. J Neuroimmune Pharmacol
21. Kubota K, Ishizaki T (1991) Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol 41:363-368
22. Leonard JV, Morris AA (2002) Urea cycle disorders. Semin Neonatol 7:27-35 (Pubitemid 34742217)
23. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE (1993) Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 151:2132-2141 (Pubitemid 23235686)
24. Mondal S, Martinson JA, Ghosh S, Watson R, Pahan K (2012a) Protection of Tregs, suppression of Th1 and Th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline. PLoS ONE 7:e51869
25. Mondal S, Roy A, Jana A, Ghosh S, Kordower JH, Pahan K (2012b) Testing NF-kappaB-based therapy in hemiparkinsonian monkeys. J Neuroimmune Pharmacol 7:544-556
26. Nair B (2001) Final report on the safety assessment of Benzyl Alcohol, Benzoic Acid, and Sodium Benzoate. Int J Toxicol 20(Suppl 3):23-50
27. Nathan C (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051-3064
28. Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, Tan EK, Dawson VL, Dawson TM, Yu F, Lim KL (2009) Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 29:11257-11262
29. Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 266:4244-4250 (Pubitemid 21909347)
30. Roy A, Ghosh A, Jana A, Liu X, Brahmachari S, Gendelman HE, Pahan K (2012) Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS ONE 7:e38113
31. Saha RN, Pahan K (2006) Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal 8:929-947 (Pubitemid 44036510)
32. Saha RN, Jana M, Pahan K (2007) MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J Immunol 179:7101-7109
33. Scaglia F, Carter S, O'Brien WE, Lee B (2004) Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab 81(Suppl 1):S79-S85 (Pubitemid 38402240)
34. Toth B (1984) Lack of tumorigenicity of sodium benzoate in mice. Fundam Appl Toxicol 4:494-496
35. Wink DA, Kasprzak KS, Maragos CM, Elespuru RK, Misra M, Dunams TM, Cebula TA, Koch WH, Andrews AW, Allen JS et al (1991) DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254:1001-1003 (Pubitemid 21917428)
36. Zhou W, Freed CR (2005) DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 280:43150-43158 (Pubitemid 43049281)